Cargando…
TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
BACKGROUND: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. While NTRK gene fusions are predictive of benefit from tropomyosin receptor kinase inhibitors regardless of tumor type, the prognostic significance of NTRK gene fusions in a pan-tumor...
Autores principales: | Bazhenova, Lyudmila, Lokker, Andrew, Snider, Jeremy, Castellanos, Emily, Fisher, Virginia, Fellous, Marc, Nanda, Shivani, Zong, Jihong, Keating, Karen, Jiao, Xiaolong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105201/ https://www.ncbi.nlm.nih.gov/pubmed/33893941 http://dx.doi.org/10.1007/s11523-021-00815-4 |
Ejemplares similares
-
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
por: Garcia-Foncillas, Jesus, et al.
Publicado: (2022) -
Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists
por: Klink, Andrew J, et al.
Publicado: (2022) -
TRK inhibitors in TRK fusion-positive cancers
por: Drilon, A
Publicado: (2019) -
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
por: Yang, James C. H., et al.
Publicado: (2022) -
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
por: Chen, Yu, et al.
Publicado: (2018)